Last reviewed · How we verify
TIV-2X Darwin influenza vaccine
TIV-2X Darwin influenza vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development.
At a glance
| Generic name | TIV-2X Darwin influenza vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIV-2X Darwin influenza vaccine CI brief — competitive landscape report
- TIV-2X Darwin influenza vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about TIV-2X Darwin influenza vaccine
What is TIV-2X Darwin influenza vaccine?
TIV-2X Darwin influenza vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes TIV-2X Darwin influenza vaccine?
TIV-2X Darwin influenza vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
What development phase is TIV-2X Darwin influenza vaccine in?
TIV-2X Darwin influenza vaccine is in Phase 1.